LY3478045

LY3478045 is an investigational small molecule drug developed by Eli Lilly. It acts as a selective inhibitor of ketohexokinase (KHK), an enzyme that plays a key role in fructose metabolism by catalyzing the phosphorylation of fructose to fructose-1-phosphate. By inhibiting KHK, LY3478045 may modulate metabolic pathways associated with disorders linked to excessive fructose intake. The compound has been evaluated in Phase 1 clinical trials primarily for safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants. As of now, there are no approved indications or known adverse events reported for this agent.